Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study)

Open access

Abstract

BACKGROUND: Anticoagulation is recommended as standard of care for venous thromboembolism (VTE) (pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which unfractionated heparin (UFH) and warfarin are used in Japan. In the multi-regional AMPLIFY study, a fixed-dose regimen of apixaban alone was non-inferior to conventional therapy for treatment of PE/DVT and was associated with significantly fewer bleeding events. METHODS AND RESULTS: Japan phase 3 study (AMPLIFY-J), randomized, active-controlled, open-label study in Japanese subjects with acute PE/DVT, was designed based on AMPLIFY. Key objectives were to investigate safety and efficacy of apixaban in symptomatic PE/DVT subjects during 24-week treatment. UFH/warfarin was used as control treatment. Apixaban was initiated at 10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks. All endpoints and imaging for thrombotic burden were assessed by an event adjudication committee. Eighty subjects were randomized, 33 subjects (41.3%) were aged <65 years. Proportion of major/clinically relevant non-major bleeding was lower in apixaban (7.5%) compared with well-controlled UFH/warfarin (28.2%; median TTR, 70.4%). [corrected]. Recurrent VTE occurred in no subjects in apixaban and in 1 subject in UFH/warfarin. Thrombotic burden results were similar in both groups. Proportions of subjects with adverse events was generally similar in both groups. CONCLUSIONS: Apixaban was well-tolerated and had a favorable safety profile. No clinically important efficacy difference compared with UFH/warfarin was observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1253/circj.cj-15-0195

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 67

Metadata

Authors
Nakamura, M., Nishikawa, M., Komuro, I., Kitajima, I., Uetsuka, Y., Yamagami, T., Minamiguchi, H., Yoshimatsu, R., Tanabe, K., Matsuoka, N., Kanmuri, K., & Ogawa, H.
Affiliations
  • Mie University (JP)
  • Mie University Hospital (JP)
  • The University of Tokyo (JP)
  • University of Toyama (JP)
  • Tokyo Women's Medical University (JP)
  • Kōchi University (JP)
  • Wakayama Medical University (JP)
  • Pfizer (Japan) (JP)
  • National Cerebral and Cardiovascular Center (JP)
Venue
Circulation Journal
Published
2015
Volume
79
Issue
6
Pages
1230-1236
ISSN
  • 1346-9843 (ISSN-L)
  • 1347-4820
OpenAlex
W1973598884
Cited by
67
References
13
Citations by year
2025: 2 · 2024: 1 · 2023: 9 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 3 · 2018: 13 · 2017: 12 · 2016: 8
FWCI
11.20
Type
journal article
Language
en
Open access
Locations
  • Circulation Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (26461067)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
apixaban, venous thromboembolism, pulmonary embolism, deep vein thrombosis, anticoagulation, unfractionated heparin, warfarin, bleeding risk, recurrent venous thromboembolism, Japanese patients
MeSH terms
Aged, Aged, 80 and over, Anticoagulants, Female, Hemorrhage, Heparin, Humans, Japan, Male, Middle Aged, Pulmonary Embolism, Pyrazoles, Pyridones, Recurrence, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). https://app.cochat.ai/papers/10.1253/circj.cj-15-0195
The paper
Nakamura, M., Nishikawa, M., Komuro, I., Kitajima, I., Uetsuka, Y., Yamagami, T., Minamiguchi, H., Yoshimatsu, R., Tanabe, K., Matsuoka, N., Kanmuri, K., & Ogawa, H. (2015). Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). Circulation Journal. https://doi.org/10.1253/circj.cj-15-0195

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.